Mount Sinai Health System, based in New York City, will adopt an artificial intelligence-powered platform from SOPHiA GENETICS to expand its cancer research and genomic testing capabilities.
The health system plans to use the SOPHiA DDM Platform to strengthen next-generation sequencing for both blood cancers and solid tumors, supporting care for more than 4,000 oncology patients annually. Mount Sinai is a National Cancer Institute-designated comprehensive cancer center.
The platform is designed to detect and interpret complex genomic variants while streamlining laboratory workflows, reducing manual analysis time and consolidating multiple steps in the testing process, according to an April 16 news release.
Mount Sinai’s molecular pathology team will use the technology to analyze genomic data at scale and improve operational efficiency.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
